4//SEC Filing
BIOCEPT INC 4
Accession 0000899243-17-001973
CIK 0001044378operating
Filed
Jan 25, 7:00 PM ET
Accepted
Jan 26, 6:05 AM ET
Size
15.1 KB
Accession
0000899243-17-001973
Insider Transaction Report
Form 4
BIOCEPT INCBIOC
Yu Fan
10% Owner
Transactions
- Disposition to Issuer
Common Stock
2017-01-19$1.10/sh−254,893$280,382→ 0 total - Disposition to Issuer
Common Stock
2017-01-17$1.10/sh−876,399$964,039→ 804,601 total - Disposition to Issuer
Common Stock
2017-01-18$1.10/sh−549,708$604,679→ 254,893 total
Transactions
- Disposition to Issuer
Common Stock
2017-01-19$1.10/sh−254,893$280,382→ 0 total - Disposition to Issuer
Common Stock
2017-01-18$1.10/sh−549,708$604,679→ 254,893 total - Disposition to Issuer
Common Stock
2017-01-17$1.10/sh−876,399$964,039→ 804,601 total
Ally Bridge LB Management Ltd
10% Owner
Transactions
- Disposition to Issuer
Common Stock
2017-01-17$1.10/sh−876,399$964,039→ 804,601 total - Disposition to Issuer
Common Stock
2017-01-19$1.10/sh−254,893$280,382→ 0 total - Disposition to Issuer
Common Stock
2017-01-18$1.10/sh−549,708$604,679→ 254,893 total
Li Bin
10% Owner
Transactions
- Disposition to Issuer
Common Stock
2017-01-17$1.10/sh−876,399$964,039→ 804,601 total - Disposition to Issuer
Common Stock
2017-01-18$1.10/sh−549,708$604,679→ 254,893 total - Disposition to Issuer
Common Stock
2017-01-19$1.10/sh−254,893$280,382→ 0 total
Footnotes (3)
- [F1]Ally Bridge LB Healthcare Master Fund Limited (the "Master Fund") directly held the disposed Common Stock and currently holds warrants to purchase 1,681,000 shares of Common Stock.. Ally Bridge LB Management Limited ("LB Management") owns the sole voting share of the Master Fund. Mr. Fan Yu and Mr. Bin Li are the shareholders and directors of LB Management. LB Management, by virtue of it being the holder of the sole voting share of the Master Fund, and each of Mr. Yu and Mr. Li, by virtue of being a shareholder and director of LB Management, may be deemed to have voting control and investment discretion over any shares held by the Master Fund. Each of LB Management, Mr. Yu and Mr. Li disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein, if any.
- [F2](continued from footnote 1) This Form 4 shall not be deemed an admission that any of them are the beneficial owners of, or have any pecuniary interest in, such securities for any purposes. By virtue of the transactions described in that certain statement on Schedule 13D/A filed in January 2017, by the Reporting Persons, pursuant to Section 13(d)(3) of the Securities Exchange Act of 1934 (the "Exchange Act"), the Reporting Persons may, based on facts described elsewhere in the Schedule 13D, be considered to be a "group"; however, neither the filing of this Form 4 nor any of its contents shall be deemed to constitute an admission by such persons that such a group exists.
- [F3]All 1,681,000 shares of Common Stock held by the Master Fund were disposed in a series of sales of the Common Stock on January 17, 2017, January 18, 2017 and January 19, 2017. The Master Fund still holds warrants to purchase 1,681,000 shares of Common Stock. The warrants held by the Master Fund represent 8.76% of the Common Stock, calculated based on 19,180,397 shares of Commons Stock, which is the total of (i) 17,499,397 shares of the Issuer's Common Stock outstanding as of November 4, 2016, as reported in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2016 filed with the SEC on November 10, 2016; and (ii) 1,681,000 shares of Common Stock issuable upon exercise of warrants held by the Master Fund.
Documents
Issuer
BIOCEPT INC
CIK 0001044378
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001044378
Filing Metadata
- Form type
- 4
- Filed
- Jan 25, 7:00 PM ET
- Accepted
- Jan 26, 6:05 AM ET
- Size
- 15.1 KB